|Videos|December 6, 2022
Regulatory Considerations for Cell & Gene Therapies
Author(s)PPD
The first segment of this five-part PPD Tech Talk series on A CMC Roadmap for Cell and Gene Therapies, Katherine Hanson, Ph.D., associate director at PPD Laboratory services, GMP Lab, discusses regulatory considerations for cell and gene therapies.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Lilly Invests $3.5B in Pennsylvania Injectable Medicine Facility
2
Navigating the Complex Risks of Accelerated Pharmaceutical Launches
3
Securing Radiopharma and GLP-1 Supply Chains Through 2026 M&A
4
Repertoire Immune Medicines and Lilly Collaborate on Treatments for Autoimmune Diseases
5